GlassScriptPhysician profile
Alice Chang
NPI 1568737484
$3,605.22
in general payments reported to CMS, 2019-2025
26 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.32 · 2020: $86.68 · 2021: $33.29 · 2022: $42.11 · 2023: $785 · 2024: $1,375 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $617.36 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $485.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $472.60 | 2021-2025 | |
| Philips North America LLC | $428.02 | 2022-2025 | (5044) Mcot, (Ck4) Mcot, Extended Holter |
| Exact Sciences Corporation | $222.73 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $201.62 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $188.48 | 2021-2025 | |
| Amgen INC. | $174.09 | 2024-2025 | Evenity, Prolia, Prolia |
| Verity Pharmaceuticals INC. | $130.43 | 2024-2025 | Tlando |
| Astrazeneca Pharmaceuticals LP | $119.59 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $119.46 | 2025 | |
| Corcept Therapeutics | $64.79 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.40 | 2023-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.74 | 2024 | Jardiance, Tradjenta |
| Baxter Healthcare | $39.91 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.46 | 2025 | Gardasil 9, Capvaxive |
| Abbott Laboratories | $24.13 | 2024 | |
| Irhythm Technologies, INC. | $24.04 | 2024 | Zio Monitor, Zio Xt Patch |
| Amarin Pharma, INC. | $23.85 | 2020 | |
| Dexcom, INC. | $23.83 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $23.48 | 2025 | |
| Acadia Pharmaceuticals INC | $23.05 | 2023 | Nuplazid |
| Inspire Medical Systems, INC. | $21.67 | 2025 | Inspire |
| Phadia US INC. | $18.40 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $17.38 | 2023 | Quviviq |
| Tolmar, INC. | $15.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.